Human papillomavirus 9-valent vaccine, recombinant (Merck & CO)

重组九价人乳头瘤病毒疫苗(默沙东)

Report date: 2026/05/20 20:02:01

Base Information

Drug NameHuman papillomavirus 9-valent vaccine, recombinant (Merck & CO)
Drug Alias Name重组人乳头瘤病毒9价疫苗（默克）Recombinant Human Papillomavirus 9-Valent (Types 6,11,16,18,31,33,45,52,58）VaccineGardasil9九价人乳头瘤病毒疫苗(酿酒酵母)加卫苗 +[21] 
ClassificationVaccines > National Immunization Program > Non-immunization program vaccine(Class II)Vaccines > Development/production technology > Genetically engineered subunit vaccineVaccines > Biological material > Viral vaccine +[5] 
Mechanisms of ActionImmunostimulants
TargetsNot applicable
Therapy Area/IndicationsRespiratory papillomatosisVulvar Intraepithelial NeoplasiaAnal intraepithelial neoplasia +[21] 
Global Approved IndicationsVulvar NeoplasmsVaginal NeoplasmsUterine Cervical Neoplasms +[6] 
Approved Indications in ChinaCondylomata Acuminata
Original Approved Country/TerritoryUnited States
Original Approved Date2014/12/10
Country/TerritoryCzechiaBelgiumCanada +[32] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesMerck & Co Inc
China Registration ClassN/A

Develop Information

Active CompaniesMsd Ireland (Carlow)University Of California San FranciscoWeill Medical College of Cornell University +[16] 
Inactive CompaniesBoston Medical Center IncNational Cancer Institute
Active IndicationsRespiratory papillomatosisVulvar Intraepithelial NeoplasiaAnal intraepithelial neoplasia +[20] 
Inactive IndicationsAdenocarcinoma in Situ

Other Information

ATC CodeJ07BM03
Related LinksWikipediaKEGG